573 related articles for article (PubMed ID: 31290990)
1. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
2. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
5. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
Saluja R; Everest L; Cheng S; Cheung M; Chan KKW
JAMA Oncol; 2019 Aug; 5(8):1188-1194. PubMed ID: 31095255
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration.
Liang F; Zhang S; Wang Q; Li W
BMC Cancer; 2020 Aug; 20(1):823. PubMed ID: 32867707
[TBL] [Abstract][Full Text] [Related]
8. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
[TBL] [Abstract][Full Text] [Related]
9. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
10. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS.
Jiang Q; Feng M; Li Y; Lang J; Wei H; Yu T
Front Pharmacol; 2020; 11():574511. PubMed ID: 33390946
[No Abstract] [Full Text] [Related]
11. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
[TBL] [Abstract][Full Text] [Related]
12. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
15. The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.
Lin S; Huang Y; Dong L; Li M; Wang Y; Gu D; Wu W; Nian D; Luo S; Huang X; Xu X; Weng X
Front Pharmacol; 2023; 14():1114304. PubMed ID: 36909180
[No Abstract] [Full Text] [Related]
16. Association between control group therapy and magnitude of clinical benefit of cancer drugs.
Molto C; Tibau A; Bujosa A; Tapia JC; Mittal A; Tamimi F; Amir E
Sci Rep; 2022 Dec; 12(1):21342. PubMed ID: 36494465
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review.
Mohamed A; Salman B; Shaikh AJ
J Oncol Pharm Pract; 2024 May; ():10781552241252100. PubMed ID: 38710475
[TBL] [Abstract][Full Text] [Related]
18. Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.
Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
JAMA Oncol; 2018 Mar; 4(3):326-332. PubMed ID: 29285547
[TBL] [Abstract][Full Text] [Related]
19. ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Cherny NI; Dafni U; Bogaerts J; Latino NJ; Pentheroudakis G; Douillard JY; Tabernero J; Zielinski C; Piccart MJ; de Vries EGE
Ann Oncol; 2017 Oct; 28(10):2340-2366. PubMed ID: 28945867
[TBL] [Abstract][Full Text] [Related]
20. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Kiesewetter B; Dafni U; de Vries EGE; Barriuso J; Curigliano G; González-Calle V; Galotti M; Gyawali B; Huntly BJP; Jäger U; Latino NJ; Malcovati L; Oosting SF; Ossenkoppele G; Piccart M; Raderer M; Scarfò L; Trapani D; Zielinski CC; Wester R; Zygoura P; Macintyre E; Cherny NI;
Ann Oncol; 2023 Sep; 34(9):734-771. PubMed ID: 37343663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
